Genedata Signs Agreement with the Fiehn Laboratory at UC Davis for Refiner MS and Analyst Software
Genedata has announced an agreement with the Fiehn Laboratory at the University of California, Davis, for the provision of the Expressionist software platform for biomarker discovery. Both Refiner MS and Analyst modules will be used for mass spectrometry-based metabolomics analyses to classify patient samples and identify biomarkers.
Genedata’s Refiner MS software module performs high-throughput processing and automated quality analysis of mass spectrometry-based proteomics and metabolomics data.
Refiner MS can enable researchers to process hundreds of gigabytes of data simultaneously, while Analyst provides a statistical analysis platform that allows these processed data to be compared with microarrays, bead-based assays, qPCR, 2D-PAGE, 2D-DIGE and NMR data, as well as additional types of MS data. This integrated view helps researchers to understand the action of all biomolecules in a single, comprehensive system.
Dr. Oliver Fiehn, Associate Professor at the UC Davis Genome Center, explained, “Given our extensive work with infusion MS and LC-MS, Genedata’s ability to work concurrently with both the raw data and extracted peaks will greatly facilitate our research. There are other systems available to handle portions of our workflow, but Genedata is unique in their capability to handle the breadth of our research processes. Their ability to handle hundreds of samples and hundreds of gigabytes of data simultaneously combined with the support for all of the MS hardware providers and MS setups made Genedata the obvious choice for us.”
“We feel that the combination of the Refiner MS and Analyst modules is a powerful enhancer to our biomarker detection efforts, and will enable our researchers to identify biomarkers that could be missed using other methods and tools,” Fiehn continued.
Dr. Jens Hoefkens, Managing Director of Genedata Inc., said, “We are delighted that Genedata software has been selected by researchers at UC Davis. We consider this agreement as further validation that our in silico offerings provide compelling advantages to scientists in prominent life sciences research institutions. We look forward to working with the Genome Center in their efforts to find novel approaches for identifying metabolites.”